Else Nutrition (TSXV:BABY) is Another of Rich’s Top Picks for 2020

Else Nutrition

Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF) is a food and nutrition company that focuses on researching, developing, manufacturing, marketing, selling, and/or licensing plant-based food and nutrition products. These products are targeted for the infant, toddler, children, and adult markets.

Rich first brought BABY to the attention of his community in October. Just days after that video, the stock rose an astounding 61%! Now, as 2020 quickly approaches, Rich returns with another bullish BABY profile. 

“You need to put BABY on your watch list, you need to put it on your radar,” he says. “I think Else Nutrition is going to be a beast in 2020.”

The Plant-Based Food and Formula Boom

You most likely already know about the great success of Beyond Meat (NASDAQ:BYND). The alternate meat stock had the best IPO of 2019, primarily because it has the first-mover advantage delivering plant-based foods to hungry consumers. 

But plant-based foods aren’t just replacing meat products like burgers, pork, and chicken. They’re also creating healthier and safer food for babies, children, and adults.

Enter Your E-mail Address To Subscribe

* indicates required

The worldwide industry for infant formula is expected to reach $90 billion in value by 2025. As more parents than ever before are looking for healthier options for their children, Else Nutrition’s breakthrough, 100% plant-based, non-soy infant formula could not come at a better time.

Else Nutrition’s First Mover Advantage

The formula is the first of its kind on the market. Made from almonds and buckwheat, Else Nutrition’s formula is free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens. This makes it a healthier and more natural option for toddlers (12–36 months) than dairy-based baby formulas.

Right now, the vast majority of infant formulas are milk-based. This unfortunately ignores the fact that cow’s milk is the number one allergen for children aged five or younger. Milk allergies currently affect half of all food-allergic children in America who are less than one year old.

On top of that, nearly all alternatives to milk-based formulas are soy-based. Yet approximately 40% percent of children allergic to cow’s milk are also allergic to soy milk.

This means there are millions of children who can’t drink cow’s milk nor any of the alternatives, save for Else Nutrition’s 100% plant-based formula. This kind of exclusive market reach is unprecedented, especially in a market as important as children’s health and nutrition.

In addition to its strong product offering, Else Nutrition has very strong IP protection. This is an important part of its plan to capitalize on being the first mover in the plant-based infant formula space.

BABY’s formula has been granted patents in 20 countries, including the United States, Australia, Japan, Ukraine, Israel, Russia, South Africa, and New Zealand. The company also has a further 50+ patents pending.

Finally, Else Nutrition is already earning revenue in Israel from the sale of its vegan baby snacks and various accessories. These products generated $900,000 for the company last year and will be launched in the US next year.

(Boss) BABY’s Performance

This morning, BABY stock jumped 16%, from $0.37 to $0.43. As the company gets ever closer to launching its products on the American market, investors and analysts are sure to take note of this exciting stock.

“We’ve got, like, three months before this BABY explodes,” says Rich. “They are pre-revenue, but they’re not far from it. In my opinion they are going to at least $1.00 next year, once they start posting revenue.”

What do you think? Is BABY bound to take off? Let us know what you think.

Featured image: DepositPhotos © vitmarkov

Please See Disclaimer

If You Liked This Article Click To Share


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on richtvlive.com should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.